Dexbrompheniramine

Summary

Dexbrompheniramine (CHEMBL1201287) is an approved small-molecule H1-receptor antagonist (ATC R06AB56); indicated across 1 condition including allergic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AB56 (+1 more)
• Indications: 1 condition
• Chemistry: 319.24 Da · C16H19BrN2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201287
Name	Dexbrompheniramine
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	16960
ChEBI	CHEBI:59269
ATC	R06AB56, R06AB06
Molecular formula	C16H19BrN2
Molecular weight	319.24
InChIKey	ZDIGNSYAACHWNL-HNNXBMFYSA-N

SMILES: CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2

IUPAC name: (3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine

ChEBI definition: The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.

Pharmacological roles (ChEBI): H1-receptor antagonist, anti-allergic agent.

Also known as: Brompheniramine d-form, Brompheniramine, (s)-, Dexbromfeniramina, Dexbrompheniramine, SID90341837, SID29216402, DEXBROMPHENIRAMINE, dexbrompheniramine

Parent form; salt/anhydrous children: CHEMBL1200638

Patent coverage: 1,064 distinct patent families (3,796 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Alpha-2B adrenergic receptor, D(1A) dopamine receptor, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Sodium-dependent noradrenaline transporter, 5-hydroxytryptamine receptor 2A, Sodium-dependent serotonin transporter, Histamine H1 receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HRH1	8.2	AC50	6.3	nM	CHEMBL_ACT_25211989
SLC6A4	7.62	AC50	23.8	nM	CHEMBL_ACT_25151033
SLC6A3	5.87	AC50	1340	nM	CHEMBL_ACT_25124665
KCNH2	5.49	AC50	3260	nM	CHEMBL_ACT_25117088
CHRM2	5.44	AC50	3662	nM	CHEMBL_ACT_25195442
ADRA2B	5.34	AC50	4600	nM	CHEMBL_ACT_25143191
SLC6A4	5.33	AC50	4700	nM	CHEMBL_ACT_25149834
CHRM1	5.05	AC50	8831	nM	CHEMBL_ACT_25209956
HRH3	5.03	AC50	9397	nM	CHEMBL_ACT_25199238

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	4	MONDO:0005271	MONDO:0005271

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).